Dogwood Therapeutics Announces Third Quarter 2026 Financial Results
Dogwood Therapeutics reported Q3 2026 net loss of $4.9 million ($0.14 per share), with $0.1 million in first-ever licensing revenue from the PRIDCor agreement. The Halneuron Phase 2b trial in chemotherapy-induced neuropathic pain is fully enrolled with 239 patients, and top-line results are expected this November — the company's key near-term catalyst. Dogwood closed a $5 million private placement with its largest shareholder Sealbond Limited (a CK Life Sciences subsidiary); combined with $4.9 million of cash, runway extends only through Q1 2027.
Key figures
- Revenue
- 100000
- Runway
- through Q1 2027
- Net loss
- 4882942
- Cash on hand
- 4948266
- Lte patients
- 95
- Ga expense q3
- 1576219
- Rd expense q3
- 3352977
- Phase2b cinp patients
- 239
- Private placement usd
- 5000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.